Charvi Mahuli

Options for minimizing delayed access of innovative medicines in the European Union. Aims at investigating the current hurdles faced by industries in providing early patient access and targeting the unmet medical needs by focusing on: Difference in the early access tools of the EU, USA and Japan, Industrial challenges in opting for EAPs 1.Planning timeframes 2.Clinical Trials Outcome 3.Difference in EMA & HTA requirements

Purification and analysis of synergistic toxins from Jameson’s mamba.  Independently collecting information on isolation & purification of the Synergistic Toxins from freeze-dried crude venom obtained from Uganda. Planning hands-on Chromatographies: Size exclusion, ion exchange and reversed-phase high performance liquid chromatography. Developing liquid chromatography mass spectrometry and Trypsin-Chymotrypsin digestion data analysis

Microbiology, Enzymology, Proteomics, Genetic Engineering, Spectroscopy, Tissue Culture, Molecular biology, Cell Biology, Histochemistry, Cytochemistry, Developmental Biology, Genomics, Bioinformatics, Plant Biotechnology, Immunology & Virology